144 related articles for article (PubMed ID: 20840444)
1. Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.
Gueorguieva I; Jackson K; Wrighton SA; Sinha VP; Chien JY
Br J Clin Pharmacol; 2010 Oct; 70(4):523-36. PubMed ID: 20840444
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D6*17 and CYP2D6*29, When Compared with Normal Metabolizers.
Marasanapalle VP; Masimirembwa C; Sivasubramanian R; Sayyed S; Weinzierl-Hinum A; Mehta D; Kapungu NN; Kanji C; Thelingwani R; Zack J
J Clin Pharmacol; 2024 May; 64(5):578-589. PubMed ID: 37803948
[TBL] [Abstract][Full Text] [Related]
3. Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus.
Boni J; Abbas R; Leister C; Burns J; Jordan R; Hoffmann M; DeMaio W; Hug B
Cancer Chemother Pharmacol; 2009 Jul; 64(2):263-70. PubMed ID: 19015855
[TBL] [Abstract][Full Text] [Related]
4. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics.
Furman KD; Grimm DR; Mueller T; Holley-Shanks RR; Bertz RJ; Williams LA; Spear BB; Katz DA
Pharmacogenetics; 2004 May; 14(5):279-84. PubMed ID: 15115913
[TBL] [Abstract][Full Text] [Related]
5. The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine.
Nguyen HQ; Callegari E; Obach RS
Drug Metab Dispos; 2016 Oct; 44(10):1569-78. PubMed ID: 27440861
[TBL] [Abstract][Full Text] [Related]
6. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
[TBL] [Abstract][Full Text] [Related]
7. Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling.
Feng Y; Pollock BG; Ferrell RE; Kimak MA; Reynolds CF; Bies RR
Br J Clin Pharmacol; 2006 May; 61(5):558-69. PubMed ID: 16669849
[TBL] [Abstract][Full Text] [Related]
8. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
[TBL] [Abstract][Full Text] [Related]
9. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers.
Madani S; Barilla D; Cramer J; Wang Y; Paul C
J Clin Pharmacol; 2002 Nov; 42(11):1211-8. PubMed ID: 12412819
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.
Hynes SM; Wickremsinhe E; Zhang W; Decker R; Ott J; Chandler J; Mitchell M
Biopharm Drug Dispos; 2015 Jan; 36(1):49-63. PubMed ID: 25296725
[TBL] [Abstract][Full Text] [Related]
11. Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers.
Chen Y; Zhou D; Tang W; Zhou W; Al-Huniti N; Masson E
J Clin Pharmacol; 2018 Apr; 58(4):485-493. PubMed ID: 29193123
[TBL] [Abstract][Full Text] [Related]
12. Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole.
Lehr T; Staab A; Trommeshauser D; Schaefer HG; Kloft C
Clin Pharmacokinet; 2010; 49(1):53-66. PubMed ID: 20000889
[TBL] [Abstract][Full Text] [Related]
13. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
14. CYP2D6 Genotype Phenotype Discordance Due to Drug-Drug Interaction.
Monte AA; West K; McDaniel KT; Flaten HK; Saben J; Shelton S; Abdelmawla F; Bushman LR; Williamson K; Abbott D; Anderson PL
Clin Pharmacol Ther; 2018 Nov; 104(5):933-939. PubMed ID: 29882961
[TBL] [Abstract][Full Text] [Related]
15. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
Kubo M; Koue T; Inaba A; Takeda H; Maune H; Fukuda T; Azuma J
Drug Metab Pharmacokinet; 2005 Feb; 20(1):55-64. PubMed ID: 15770075
[TBL] [Abstract][Full Text] [Related]
16. An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction.
Reese MJ; Wurm RM; Muir KT; Generaux GT; St John-Williams L; McConn DJ
Drug Metab Dispos; 2008 Jul; 36(7):1198-201. PubMed ID: 18420781
[TBL] [Abstract][Full Text] [Related]
17. Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial.
Murphy MP; Beaman ME; Clark LS; Cayouette M; Benson L; Morris DM; Polli JW
Pharmacogenetics; 2000 Oct; 10(7):583-90. PubMed ID: 11037800
[TBL] [Abstract][Full Text] [Related]
18. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
Lin J; Goosen TC; Tse S; Yamagami H; Malhotra B
J Clin Pharmacol; 2019 Nov; 59(11):1505-1518. PubMed ID: 31090092
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability.
Kerbusch T; Wählby U; Milligan PA; Karlsson MO
Br J Clin Pharmacol; 2003 Dec; 56(6):639-52. PubMed ID: 14616424
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.
Dalén P; Dahl M; Andersson K; Bertilsson L
Br J Clin Pharmacol; 2000 Feb; 49(2):180-4. PubMed ID: 10671914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
